Semisynthesis of RPR 121056A, a major metabolite of irinotecan (CPT-11)

Article abstract of DOI:10.1016/0040-4039(96)01387-1

The semisynthesis of RPR 121056A (4), a major metabolite of irinotecan (CPT-11, 2) is reported starting from SN-38 (3) and an appropriate side-chain precursor, and using a 2-step sequence. This semisynthesis is based on the 10-O-acylation of SN-38 with the conveniently protected carbamoylchloride derivative 10 followed by cleavage of the benzylic protecting groups by hydrogenolysis. Preliminary in vitro results show that RPR 121056A displays no cytotoxicity.